Healthcare Intelligence
Health Economics & Outcomes Research
Real-time intelligence, expert analysis, and verified research for the Health Economics & Outcomes Research industry. Stay ahead in 3 minutes a day.
Stay ahead of Health Economics & Outcomes Research in 3 minutes a day.
Expert-verified intelligence delivered to your inbox every morning.
Free forever. No spam. Unsubscribe anytime.
AI-enabled rare disease evidence needs validation file before access talks
ISPOR's July 2026 agenda puts algorithm validation at center of rare disease HEOR evidence planning.
Read full articleUK approves Wegovy for metabolic-associated steatohepatitis treatment
MHRA grants conditional approval for semaglutide in MASH patients, pending confirmatory study results.
Read full articleUK-US drug deal could cause 229,000 excess deaths, BMJ study warns
Research shows £45bn NHS funding diversion to new medicines may lead to preventable deaths by 2036.
Read full articleNHS must divert billions for new medicines under UK-US trade deal
BMJ analysis reveals NHS spending on new drugs must double to 0.6% GDP by 2036, costing £170m weekly.
Read full articleNICE cost-effectiveness threshold rises to £35,000 per QALY
UK raises drug approval threshold from £30,000 to £35,000 per quality-adjusted life year from April 2026.
Read full articleHealthcare costs push Texas businesses to breaking point
Rising healthcare expenses force Texas employers to seek legislative solutions for cost containment.
Read full articleISPOR lists AI and RWE as top 2 HEOR trends for 2026-2027
International society highlights AI-enabled real-world evidence generation as key priority for HEOR teams.
Read full articleUK pharma rebate rate cut from 23% to 14.5% under new VPAG agreement
Voluntary scheme for branded medicines pricing reduces industry rebate payments, increasing NHS drug costs.
Read full articleAI-enabled rare disease evidence needs validation file before access talks
ISPOR's July 2026 agenda puts algorithm validation at center of rare disease HEOR evidence planning.
Read full articleUK approves Wegovy for metabolic-associated steatohepatitis treatment
MHRA grants conditional approval for semaglutide in MASH patients, pending confirmatory study results.
Read full articleUK-US drug deal could cause 229,000 excess deaths, BMJ study warns
Research shows £45bn NHS funding diversion to new medicines may lead to preventable deaths by 2036.
Read full articleNHS must divert billions for new medicines under UK-US trade deal
BMJ analysis reveals NHS spending on new drugs must double to 0.6% GDP by 2036, costing £170m weekly.
Read full articleNICE cost-effectiveness threshold rises to £35,000 per QALY
UK raises drug approval threshold from £30,000 to £35,000 per quality-adjusted life year from April 2026.
Read full articleHealthcare costs push Texas businesses to breaking point
Rising healthcare expenses force Texas employers to seek legislative solutions for cost containment.
Read full articleISPOR lists AI and RWE as top 2 HEOR trends for 2026-2027
International society highlights AI-enabled real-world evidence generation as key priority for HEOR teams.
Read full articleUK pharma rebate rate cut from 23% to 14.5% under new VPAG agreement
Voluntary scheme for branded medicines pricing reduces industry rebate payments, increasing NHS drug costs.
Read full articleStay ahead of Health Economics & Outcomes Research in 3 minutes a day.
Live opportunity intelligence for your market, delivered to your inbox every morning. Read it over coffee.
Free forever. No spam. Unsubscribe anytime.